565 related articles for article (PubMed ID: 17275793)
1. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
[TBL] [Abstract][Full Text] [Related]
2. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
[TBL] [Abstract][Full Text] [Related]
3. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
4. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
6. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
[TBL] [Abstract][Full Text] [Related]
8. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S
Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
10. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
13. Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice.
Ito T; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):121-5. PubMed ID: 21788124
[TBL] [Abstract][Full Text] [Related]
14. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
15. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
16. Possible role of propofol's cyclooxygenase-inhibiting property in alleviating dopaminergic neuronal loss in the substantia nigra in an MPTP-induced murine model of Parkinson's disease.
Kubo K; Inada T; Shingu K
Brain Res; 2011 Apr; 1387():125-33. PubMed ID: 21376018
[TBL] [Abstract][Full Text] [Related]
17. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
18. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease.
Kurosaki R; Muramatsu Y; Kato H; Araki T
Pharmacol Biochem Behav; 2004 May; 78(1):143-53. PubMed ID: 15159144
[TBL] [Abstract][Full Text] [Related]
19. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
Jung HW; Son HY; Jin GZ; Park YK
Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
Hu SC; Chang FW; Sung YJ; Hsu WM; Lee EH
J Pharmacol Exp Ther; 1991 Dec; 259(3):1379-87. PubMed ID: 1684822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
